N.B. Investments go down as well as up so there is always a danger you could make a loss. Nothing here is personalised advice, if unsure you should seek advice.
Dominic Rowles | Wed 14 March 2018
This fund invests in some of the smallest companies listed on the UK stock market. In our most recent update, we examine the fund’s performance and its current positioning.
Dominic Rowles | Tue 13 March 2018
Nick train has positioned the fund to benefit from a number of themes he expects to unfold over the coming years and decades. We look at these themes in more detail and share our view on the fund’s prospects.
Dominic Rowles | Fri 09 March 2018
In this update we review the fund’s recent performance and share the manager’s outlook for Japanese companies.
Kate Marshall | Thu 08 March 2018
The FP Argonaut European Alpha Fund has been removed from the Wealth 150 list of our favourite funds for new investment.
Kate Marshall | Tue 06 March 2018
Alexander Darwall seeks companies with a unique and sustainable competitive advantage. We look at how this has impacted recent performance and consider the fund's future prospects.
Kate Marshall | Fri 02 March 2018
We speak to the emerging markets equity team at Newton to find out what’s driven recent performance, and their outlook for dividend growth.
Kate Marshall | Thu 01 March 2018
We speak to the Asian equity team at Newton to find out what’s driven recent performance, and their outlook for dividend growth.
Kate Marshall | Thu 22 February 2018
The Janus Henderson Cautious Managed Fund has been removed from the Wealth 150+.
Dominic Rowles | Thu 01 March 2018
Paul Spencer has been investing in medium-sized companies with outstanding prospects for more than two decades. We look at where he is currently finding value
Dominic Rowles | Fri 16 February 2018
The AXA Framlington Biotech Fund aims to make the most of the opportunities on offer in one of the most interesting and exciting areas of the stock market. We review the fund’s performance and share our view on its prospects.
1 2 3 4 5 6 7 8 9 10
Important information - No news or research item is a personal recommendation to deal.